Hypothalamic neurokinin signalling and its application in reproductive medicine-Reference-Cited by-同舟云学术

Hypothalamic neurokinin signalling and its application in reproductive medicine

Published:2022-02 Issue: Volume:230 Page:107960
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Skorupskaite Karolina,Anderson Richard A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference123 articles.

1. Naturally occurring and experimentally induced rhesus macaque models for polycystic ovary syndrome: Translational gateways to clinical application;Abbott;Medical Sciences (Basel),2019

2. The effects of hormone replacement therapy on hypothalamic neuropeptide gene expression in a primate model of menopause;Abel;The Journal of Clinical Endocrinology and Metabolism,1999

3. Treatment of uterine fibroid symptoms with Relugolix combination therapy;Al-Hendy;The New England Journal of Medicine,2021

4. Pharmacodynamic activity of the novel Neurokinin-3 receptor antagonist SJX-653 in healthy men;Anderson;The Journal of Clinical Endocrinology and Metabolism,2020

5. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days;Baird;Human Reproduction,1995

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism;Clinical Endocrinology;2024-06-21

2. Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms;Expert Opinion on Pharmacotherapy;2024-05-02

3. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants;AFR J REPROD HEALTH;2024

4. A comprehensive review of the new FIGO classification of ovulatory disorders;Human Reproduction Update;2024-02-27

5. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms;Expert Opinion on Investigational Drugs;2024-01-02